Payment overview · 2025
General Payments
$1,170.85
11 reported records · 8 companies
Healthcare provider profile · identity verified
Jason B. Karp, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · LAKE SUCCESS, NY · NPI 1376514265
Verified facts
What the public records show
CMS Open Payments records show Jason B. Karp, MD received $1,170.85 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nucala, Tezspire, Uptravi.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Uptravi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Tudorza Pressair by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 1722 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $237.34 | 20.3% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $234.74 | 20.1% | 2 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.06 | 11.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $125.00 | 10.7% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $125.00 | 10.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $120.59 | 10.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $118.76 | 10.1% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $72.36 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,170.85 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. | $382.65 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $118.76 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $114.80 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $114.80 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $72.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUCALA nucala |
2025 | Nucala | 2024 | 102 | exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
18 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
184 | 58 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
250 | 96 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
102 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
1722 | 533 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 1796 | 573 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 1722 | 533 |
| Famotidine | Famotidine | 1362 | 520 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 791 | 351 |
| Prednisone | Prednisone | 659 | 432 |
| Breo Ellipta | Fluticasone/Vilanterol | 605 | 189 |
| Azelastine Hcl | Azelastine Hcl | 371 | 170 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 353 | 131 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 324 | 108 |
| Desloratadine | Desloratadine | 321 | 130 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 292 | 93 |
| Amitriptyline Hcl | Amitriptyline Hcl | 287 | 101 |
| Dupixent Pen | Dupilumab | 286 | 49 |
| Azithromycin | Azithromycin | 282 | 171 |
| Olopatadine Hcl | Olopatadine Hcl | 268 | 159 |
| Fluticasone Propionate | Fluticasone Propionate | 265 | 118 |
| Symbicort | Budesonide/Formoterol Fumarate | 250 | 96 |
| Spiriva Respimat | Tiotropium Bromide | 248 | 93 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 243 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 100 |
| Roflumilast | Roflumilast | 234 | 69 |
| Incruse Ellipta | Umeclidinium Bromide | 216 | 69 |
| Omeprazole | Omeprazole | 215 | 69 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 184 | 58 |
| Gabapentin | Gabapentin | 173 | 69 |
| Arnuity Ellipta | Fluticasone Furoate | 170 | 48 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 161 | 76 |
| Ipratropium Bromide | Ipratropium Bromide | 160 | 64 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 152 | 77 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 151 | 77 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 137 | 77 |
| Qvar Redihaler | Beclomethasone Dipropionate | 126 | 48 |
| Theophylline Er | Theophylline Anhydrous | 118 | 37 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 103 | 49 |
| Ofev | Nintedanib Esylate | 103 | 21 |
| Nucala | Mepolizumab | 102 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 93 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 90 | 77 |
| Epinephrine | Epinephrine | 90 | 75 |
| Armodafinil | Armodafinil | 83 | 14 |
| Pulmicort Flexhaler | Budesonide | 83 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 83 | 39 |
| Opsumit | Macitentan | 82 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 82 | 46 |
| Ryaltris | Olopatadine Hcl/Mometasone | 78 | 39 |
| Alvesco | Ciclesonide | 77 | 19 |
| Mometasone Furoate | Mometasone Furoate | 68 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 54 | 18 |
| Breyna | Budesonide/Formoterol Fumarate | 54 | 25 |
| Doxepin Hcl | Doxepin Hcl | 54 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 54 | 51 |
| Qnasl | Beclomethasone Dipropionate | 49 | 22 |
| Tadalafil | Tadalafil | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 37 |
| Zafirlukast | Zafirlukast | 46 | 17 |
| Serevent Diskus | Salmeterol Xinafoate | 40 | 12 |
| Carbinoxamine Maleate | Carbinoxamine Maleate | 39 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Uptravi | Selexipag | 34 | suppressed |
| Baclofen | Baclofen | 31 | 12 |
| Dupixent Syringe | Dupilumab | 31 | suppressed |
| Winrevair | Sotatercept-Csrk | 31 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Asmanex | Mometasone Furoate | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Dulera | Mometasone/Formoterol | 28 | 17 |
| Ethambutol Hcl | Ethambutol Hcl | 27 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 26 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 26 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 26 | suppressed |
| Theo-24 | Theophylline Anhydrous | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | 11 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 25 | 18 |
| Nystatin | Nystatin | 25 | 21 |
| Striverdi Respimat | Olodaterol Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 24 |
| Pirfenidone | Pirfenidone | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 20 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | 13 |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Rifampin | Rifampin | 20 | suppressed |
| Xolair | Omalizumab | 20 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 20 | suppressed |
| Adempas | Riociguat | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | 11 |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Tezspire | Tezepelumab-Ekko | 19 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 19 | suppressed |
| Adcirca | Tadalafil | 18 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 18 | 14 |
| Flunisolide | Flunisolide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Daliresp | Roflumilast | 16 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 16 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Zileuton Er | Zileuton | 15 | suppressed |
| Fasenra Pen | Benralizumab | 14 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Colchicine | Colchicine | 13 | suppressed |
| Enstilar | Calcipotriene/Betamethasone | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Ambien Cr | Zolpidem Tartrate | 11 | suppressed |
| Ambrisentan | Ambrisentan | 11 | suppressed |
| Atovaquone | Atovaquone | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Scopolamine | Scopolamine | 11 | suppressed |
| Taclonex | Calcipotriene/Betamethasone | 11 | suppressed |
| Wakix | Pitolisant Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,170.85 · 11 records | AstraZeneca Pharmaceuticals LP | DUPIXENT, Da Vinci Surgical System, NUCALA, OPSYNVI, TEZSPIRE, UPTRAVI | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nucala play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error